Hexarelin
Get a source-linked, educational explanation from this profile.
Complete Research Guide
Open each section for the available evidence. Gaps are stated rather than inferred.
Overview
Hexarelin is listed as endocrine / ghrp-6 analog.
- •GH secretagogue
- •Cardioprotection (research)
- •Body composition
Regulatory status: Not FDA-approved; research use.
Structure & Properties
Compound: Hexarelin; also known as Examorelin, EP 23905.
Pharmacologic class: Endocrine / GHRP-6 Analog.
Known delivery routes: Subcutaneous.
Sequence, molecular weight, salt form, and excipient details are formulation-specific and are not listed unless verified by a manufacturer or laboratory COA.
How It Works
Potent ghrelin / GHS-R1a agonist — stimulates pituitary GH release; direct cardioprotective effects via GHS-R1b on cardiomyocytes; reduces cardiac fibrosis.
- •Strong GH release
- •Cardioprotective signaling in models
- •Body composition support
Human Research
Evidence grade: Pre-clinical / Observational
Evidence is primarily preclinical or observational; human effectiveness and long-term safety are not established.
Laboratory Research
Phase I/II cardiac studies; robust GH-axis data
Preclinical findings describe biological plausibility, not proven benefit in people. Animal and laboratory doses do not translate directly to human use.
Processing & Interactions
Timing and exposure
1–2× daily fasted, short cycles only (4 weeks max). Desensitization occurs rapidly.
Potential interactions and combinations to avoid
- •Other GHRPs — same class
- •MK-677
- •Concurrent long-term GH therapy
Absorption, half-life, metabolism, and clearance can vary by formulation and route. Use prescribing information when an approved product exists.
Safety & Precautions
Known or reported risks
- •Rapid desensitization with chronic use
- •Elevated cortisol and prolactin
- •Hunger stimulation
Contraindications
- •Active malignancy
- •Pregnancy
- •Active malignancy or history of hormone-sensitive tumor (GH/IGF-1 axis stimulation)
- •Active or untreated diabetic retinopathy
- •Insulin resistance, prediabetes, or poorly controlled type 2 diabetes
- •Untreated hypothyroidism or uncorrected adrenal insufficiency
- •Acromegaly, pituitary adenoma, or intracranial hypertension
- •Carpal tunnel syndrome, peripheral edema, or fluid-retentive heart failure
- •Critical illness after acute surgery, trauma, or respiratory failure
- •Severe obstructive sleep apnea (may worsen with soft-tissue growth)
- •Bleeding disorders or anticoagulant therapy without physician guidance (injection-site haematoma)
- •Active skin infection, cellulitis, or lipohypertrophy at intended injection sites
- •Inability to maintain sterile technique or safe sharps disposal
- •Not FDA-approved for human therapeutic use — no verified purity, sterility, or potency standards
- •Immunocompromised or transplant patients (unverified sterility and immunogenicity risk)
- •Concurrent participation in drug-tested sport (WADA prohibited or non-cleared substance)
- •Known hypersensitivity or prior reaction to this compound or any excipient/diluent
- •Pregnancy, attempting conception, or breastfeeding unless prescribed and monitored by a physician
- •Children and adolescents with open growth plates (unless under specialist endocrine care)
- •Active or recently treated malignancy without oncology clearance
- •Use without a confirmed diagnosis, baseline labs, and licensed clinical supervision
Unknown long-term toxicity should be assumed where controlled human data are limited. Seek urgent care for a severe or unexpected reaction.
Administration & Studied Formulations
Reference range: 100–200 mcg/dose
Frequency: 1–2× daily
Cycling: Pulsed: 4 weeks on / 4 weeks off.
Subcutaneous (SubQ)
Default route for most research and therapeutic peptides — best absorption for reconstituted powder.
31G × 5/16" insulin syringe (U-100). 100 units = 1 mL. Pinch skin at abdomen (2" from navel), outer thigh, or love handle. Insert at 45–90°. Rotate sites daily to prevent lipohypertrophy. Alcohol-swab site, air-dry, inject slow, hold 5 sec.
Dosing information is educational context, not a personal recommendation. Approved products must follow their label and prescriber instructions.
Applications & Related Therapies
Potentially complementary measures
- •Short pairing with CJC-1295 / Mod GRF for pulse amplification
Clinical use should account for diagnosis, approved alternatives, nutrition, activity, sleep, rehabilitation, current medicines, and appropriate monitoring.
Highest cortisol/prolactin bump of the GHRPs.
Cases, Considerations & Ethics
Decision framework: establish the clinical goal, confirm evidence quality and legal status, screen contraindications and interactions, compare approved alternatives, define monitoring and stopping criteria, and use shared decision-making with a licensed clinician.
Case evidence: individual reports cannot establish safety or effectiveness and should not outweigh controlled trials.
Ethics: informed consent should distinguish established care from experimental use, disclose uncertainty and cost, avoid overstated claims, and never substitute research products for medically necessary care.
- Other GHRPs
- MK
- Concurrent long
What is Hexarelin?
In plain words
Hexarelin is a peptide, a small protein-like compound that signals the body to release growth hormone. Researchers study this hormone-releasing effect and its possible ability to protect heart muscle and reduce scarring. Evidence comes from laboratory, animal, or observational research, and it is not FDA-approved. Reported risks include increased hunger, higher levels of the hormones cortisol and prolactin, and a quickly weakening response with repeated exposure.
Technical definition
Hexarelin (examorelin; EP 23905) is a peptide analog of GHRP-6 and a potent agonist of the ghrelin receptor GHS-R1a, stimulating pituitary growth hormone release. Its reported cardiac mechanisms include direct cardioprotective effects through GHS-R1b on cardiomyocytes and reduced cardiac fibrosis. Evidence is preclinical or observational; hexarelin is not FDA-approved and is designated for research use.
Function
Dosing
Recommended Time of Day
Fasted, once or twice daily — morning and pre-bed; cycle off after 4–6 weeks.
See “Timing & Interactions” below for full fasted/fed circumstances, what to avoid combining, and what pairs well.
Administration & Technique
Injection & Application Sites
- Abdomen — 2 in (5 cm) away from the navel, either side. Fastest, most consistent SubQ absorption.
- Flank / love handle — Lateral fat pad above the hip. Good rotation site when the abdomen is tender.
- Outer thigh — Upper outer quadrant, a hand-width below the hip. SubQ pinch at 45°.
Diagram is a general illustration, not a medical instruction. Rotate sites every injection, keep 1 in (2.5 cm) between recent sites, and avoid scars, moles, bruises and the navel area.
Cycling
Pulsed: 4 weeks on / 4 weeks off.
Timing & Interactions
- ·Other GHRPs — same class
- ·MK-677
- ·Concurrent long-term GH therapy
- ·Short pairing with CJC-1295 / Mod GRF for pulse amplification
Storage & Reconstitution
Reconstitution Calculator
1 mL = 100 units on a standard U-100 insulin syringe. Draw to the nearest 0.5 unit and confirm dosing with a clinician before injection.
Your Notes
Sign in to save personal notes on Hexarelin and sync them to Vial Lab.
Benefits
- ·Strong GH release
- ·Cardioprotective signaling in models
- ·Body composition support
Risks
- ·Rapid desensitization with chronic use
- ·Elevated cortisol and prolactin
- ·Hunger stimulation
Contraindications
- ·Active malignancy
- ·Pregnancy
- ·Active malignancy or history of hormone-sensitive tumor (GH/IGF-1 axis stimulation)
- ·Active or untreated diabetic retinopathy
- ·Insulin resistance, prediabetes, or poorly controlled type 2 diabetes
- ·Untreated hypothyroidism or uncorrected adrenal insufficiency
- ·Acromegaly, pituitary adenoma, or intracranial hypertension
- ·Carpal tunnel syndrome, peripheral edema, or fluid-retentive heart failure
- ·Critical illness after acute surgery, trauma, or respiratory failure
- ·Severe obstructive sleep apnea (may worsen with soft-tissue growth)
- ·Bleeding disorders or anticoagulant therapy without physician guidance (injection-site haematoma)
- ·Active skin infection, cellulitis, or lipohypertrophy at intended injection sites
- ·Inability to maintain sterile technique or safe sharps disposal
- ·Not FDA-approved for human therapeutic use — no verified purity, sterility, or potency standards
- ·Immunocompromised or transplant patients (unverified sterility and immunogenicity risk)
- ·Concurrent participation in drug-tested sport (WADA prohibited or non-cleared substance)
- ·Known hypersensitivity or prior reaction to this compound or any excipient/diluent
- ·Pregnancy, attempting conception, or breastfeeding unless prescribed and monitored by a physician
- ·Children and adolescents with open growth plates (unless under specialist endocrine care)
- ·Active or recently treated malignancy without oncology clearance
- ·Use without a confirmed diagnosis, baseline labs, and licensed clinical supervision
Regulatory
Not FDA-approved; research use
Veterinary Use (Pets)
No established veterinary protocol for Hexarelin. Consult a licensed veterinarian before considering off-label use in any species.
Full veterinary reference →Functional Groups
Cited Works
Tap any study to open the published work.